| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Children’s Hospital (Dr. Glauser), Department of Neurology, Cincinnati, OH; Children’s Hospital of Michigan (Dr. Nigro), Division of Neurology, Detroit, MI; New Jersey Comprehensive Epilepsy Center (Drs. Sachdeo and Mandelbaum), New Brunswick, NJ; CENTUC, San Miguel de Tucuman (Dr. Pasteris), Argentina; Children’s Hospital, Department of Neurology, (Dr. Weinstein) Washington, DC; Vanderbilt University, (Dr. Abou-Khalil), Medical Center, Nashville TN; Neuro-Development Center, Child & Adolescent Neurology (Dr. Frank), Norfolk, VA; Sanatorio Morra (Dr. Grinspan), Cordoba, Argentina; Pediatric Neuro (Dr. Guarino), San Jose, CA; Pediatric Neurology of Idaho (Dr. Bettis), Boise, ID; Barrow Neurological Institute, Epilepsy Clinic (Dr. Kerrigan), Phoenix, AZ; L’Hospital Ste-Justine, Service de Neurologie (Dr. Geoffroy), Montreal, Quebec, Canada; Novartis Pharmaceuticals Corporation (Drs. Jacobs, Mesenbrink, Kramer, and D’Souza), East Hanover, NJ.
Address correspondence and reprint requests to Dr. Tracy A. Glauser, Children’s Hospital Medical Center, Department of Neurology, OSB-5, 3333 Burnet Avenue, Cincinnati, OH 45229.
OBJECTIVE: To evaluate the safety and efficacy of oxcarbazepine (OXC) as adjunctive therapy in children with inadequately controlled partial seizures on one or two concomitant antiepileptic drugs (AEDs).
BACKGROUND: OXC has shown antiepileptic activity in several comparative monotherapy trials in newly diagnosed patients with epilepsy, and in a placebo-controlled monotherapy trial in hospitalized patients evaluated for epilepsy surgery.
DESIGN: A total of 267 patients were evaluated in a multicenter, randomized, placebo-controlled trial consisting of three phases: 1) a 56-day baseline phase (patients maintained on their current AEDs); 2) a 112-day double-blind treatment phase (patients received either OXC 30–46 mg/kg/day orally or placebo); and 3) an open-label extension phase. Data are reported only from the double-blind treatment phase; the open-label extension phase is ongoing.
METHODS: Children (3 to 17 years old) with inadequately controlled partial seizures (simple, complex, and partial seizures evolving to secondarily generalized seizures) were enrolled.
RESULTS: Patients treated with OXC experienced a significantly greater median percent reduction from baseline in partial seizure frequency than patients treated with placebo (p = 0.0001; 35% versus 9%, respectively). Forty-one percent of patients treated with OXC experienced a 
50% reduction from baseline in partial seizure frequency per 28 days compared with 22% of patients treated with placebo (p = 0.0005). Ninety-one percent of the group treated with OXC and 82% of the group treated with placebo reported 1 adverse event; vomiting, somnolence, dizziness, and nausea occurred more frequently (twofold or greater) in the group treated with OXC.
CONCLUSION: OXC adjunctive therapy administered in a dose range of 6 to 51 mg/kg/day (median 31.4 mg/kg/day) is safe, effective, and well tolerated in children with partial seizures.
Key words: Oxcarbazepine—Pediatric epilepsy—Partial seizures—Antiepileptic drugs—Adjunctive therapy—Trileptal.
This article has been cited by other articles:
|
|
 |
|
  F. Donati, G. Gobbi, J. Campistol, G. Rapatz, M. Daehler, Y. Sturm, A. P. Aldenkamp, and on behalf of The Oxcarbazepine Cognitive Study Gro Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology, August 22, 2006; 67(4): 679 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Glauser, R. Ayala, R. D. Elterman, W. G. Mitchell, C. B. Van Orman, L. J. Gauer, Z. Lu, and on behalf of the N159 Study Group Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures Neurology, June 13, 2006; 66(11): 1654 - 1660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Chiron, S. Tonnelier, E. Rey, M.-L. Brunet, A. Tran, P. d'Athis, J. Vincent, O. Dulac, and G. Pons Stiripentol in Childhood Partial Epilepsy: Randomized Placebo-Controlled Trial with Enrichment and Withdrawal Design J Child Neurol, June 1, 2006; 21(6): 496 - 502. [Abstract] [PDF]
|
|
|
|
|
|
J. E. Pina-Garza, R. Espinoza, D. Nordli, D. A. Bennett, S. Spirito, T. E. Stites, D. Tang, and Y. Sturm Oxcarbazepine adjunctive therapy in infants and young children with partial seizures Neurology, November 8, 2005; 65(9): 1370 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rey, C. Bulteau, J. Motte, A. Tran, Y. Sturm, J. D'Souza, S. Markabi, G. Pons, and O. Dulac Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy J. Clin. Pharmacol., November 1, 2004; 44(11): 1290 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vazquez Monotherapy in Epilepsy: Role of the Newer Antiepileptic Drugs Arch Neurol, September 1, 2004; 61(9): 1361 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, August 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]
|
|
|
|
|
|
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society Neurology, April 27, 2004; 62(8): 1261 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Glauser Behavioral and Psychiatric Adverse Events Associated With Antiepileptic Drugs Commonly Used in Pediatric Patients J Child Neurol, January 1, 2004; 19(1_suppl): S25 - S38. [Abstract] [PDF]
|
|
|
|
|
|
D. K. Nguyen and S. S. Spencer Recent Advances in the Treatment of Epilepsy Arch Neurol, July 1, 2003; 60(7): 929 - 935. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Jarrar and J. R. Buchhalter Therapeutics in Pediatric Epilepsy, Part 1: The New Antiepileptic Drugs and the Ketogenic Diet Mayo Clin. Proc., March 1, 2003; 78(3): 359 - 370. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M.A. Hirschfeld, C. L. Bowden, M. J. Gitlin, P. E. Keck, R. H. Perlis, T. Suppes, M. E. Thase, and K. D. Wagner Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision) Focus, January 1, 2003; 1(1): 64 - 110. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Glauser Integrating clinical trial data into clinical practice Neurology, June 25, 2002; 58(12_suppl_7): S6 - S12. [Full Text]
|
|
|
|
 |
|
 {blacktriangledown}Oxcarbazepine for epilepsy - a useful new choice? DTB, June 1, 2002; 40(6): 46 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Wheless Using the New Antiepilepsy Drugs in Children J Child Neurol, January 1, 2002; 17(1_suppl): S58 - S64. [Abstract] [PDF]
|
|
|
|
|
|
M. Bebin Pediatric Partial and Generalized Seizures J Child Neurol, January 1, 2002; 17(1_suppl): S65 - S69. [Abstract] [PDF]
|
|
|
|
|
|
R. Sachdeo, A. Beydoun, S. Schachter, B. Vazquez, N. Schaul, P. Mesenbrink, L. Kramer, and J. D'Souza Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures Neurology, September 11, 2001; 57(5): 864 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Managing childhood epilepsy DTB, February 1, 2001; 39(2): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
